Glucagon Receptor Antagonist Peptides
Overview
Glucagon receptor antagonist peptides are a class of molecules designed to block the glucagon receptor and prevent glucagon-mediated hepatic glucose output. These peptides typically consist of modified glucagon analogs with substitutions that convert agonist activity to antagonism.
Mechanism of Action
The therapeutic rationale focuses on lowering blood glucose in type 2 diabetes by reducing hepatic gluconeogenesis and glycogenolysis. Structural modifications also enhance metabolic stability and receptor selectivity.
Research Summary & Key Findings
Early clinical studies of peptide-based glucagon receptor antagonists demonstrated glucose-lowering efficacy but raised concerns about hepatic steatosis and increased LDL cholesterol. Development efforts have largely shifted to small molecule antagonists and monoclonal antibodies due to pharmacokinetic limitations of peptide scaffolds. Preclinical models continue to validate the glucagon receptor as a target for diabetes, though no peptide antagonist has advanced to late-stage trials.
Clinical Status
Glucagon Receptor Antagonist Peptides is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed — "Glucagon Receptor Antagonist Peptides"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Glucagon Receptor Antagonist Peptides"
Registered interventional and observational studies, including status and phase.
- PubChem — "Glucagon Receptor Antagonist Peptides"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Gastrointestinal
Octreotide (Sandostatin)
FDA ApprovedA synthetic octapeptide analog of somatostatin with a substantially longer half-life (90 minutes IV, 6 hours subcutaneou...
View detailsLanreotide (Somatuline Depot)
FDA ApprovedA synthetic octapeptide analog of somatostatin with high affinity for SSTR2 and moderate affinity for SSTR5 receptors. L...
View detailsPasireotide (Signifor)
FDA ApprovedA multireceptor-targeted somatostatin analog with high binding affinity for SSTR1, SSTR2, SSTR3, and SSTR5, particularly...
View detailsPlecanatide (Trulance)
FDA ApprovedA synthetic 16-amino acid peptide structurally related to uroguanylin, an endogenous intestinal peptide that regulates f...
View detailsStart Your Consultation
Get an AI-proposed Glucagon Receptor Antagonist Peptides protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Glucagon Receptor Antagonist Peptides.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.